Development of an automated RNA-based nuclease protection assay for the detection of expressed EML-ALK fusions, EGFR, and KRAS mutations in NSCLC. This is an ASCO Meeting Abstract from the 2013 ASCO ...
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has won U.S. Food and Drug Administration approval for RYBREVANT FASPRO, the ...
Docetaxel (D) versus docetaxel/gemcitabine (D&G) in the treatment of older patients with advanced non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary Group randomized ...
The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...
The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
AI innovations, such as the ASCO Guidelines Assistant, enhance evidence-based decision-making by providing quick access to ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
Lung cancer is the second most common cancer after breast cancer in women, after prostate cancer in men, and is the leading cause of cancer-related deaths worldwide. The proportion of lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback